Summary

Persistence Market Research has recently released a comprehensive report on the global CAR T-Cell Therapy Market. This report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.

Key Insights:

• CAR T-Cell Therapy Market Size (2024E): USD 3.7 Bn
• Projected Market Value (2033F): USD 20.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 21.3%

CAR T-Cell Therapy Market - Report Scope:

CAR T-cell therapy represents a revolutionary advancement in cancer treatment, offering personalized immunotherapy by modifying a patient’s T-cells to specifically target and destroy cancer cells. This innovative approach has demonstrated significant efficacy, especially in treating hematologic malignancies like leukemia and lymphoma. The market for CAR T-cell therapy is driven by the increasing incidence of cancer, ongoing R&D activities, and the rising adoption of precision medicine. The market encompasses both commercial applications and clinical trials, with several CAR T-cell therapies already approved by regulatory authorities.

Market Growth Drivers:

The global CAR T-cell therapy market is fueled by several key factors, including the rising cancer prevalence, which drives demand for more effective and targeted therapies. Advances in genetic engineering and cellular therapies are enabling the development of new CAR T-cell therapies with improved safety and efficacy. Additionally, growing investments in research and clinical trials, along with supportive regulatory environments, are facilitating the approval and commercialization of novel CAR T-cell therapies, contributing to market growth.

Market Restraints:

Despite its promising potential, the CAR T-cell therapy market faces challenges such as high treatment costs and complex manufacturing processes. The high price of therapy can limit accessibility, particularly in low- and middle-income countries. Moreover, the elaborate and time-consuming process of manufacturing CAR T-cells—including cell extraction, modification, and reinfusion—can restrict scalability and widespread adoption. Safety concerns, such as the risk of severe side effects like cytokine release syndrome (CRS), also present challenges that need to be addressed to improve patient outcomes.

Market Opportunities:

The CAR T-cell therapy market presents substantial growth opportunities driven by technological advancements, the expansion of indications beyond hematologic cancers, and the development of allogeneic CAR T-cell therapies, which could offer off-the-shelf solutions. The increasing focus on precision medicine and personalized treatments is expected to boost CAR T-cell therapy adoption in the coming years. Strategic partnerships between biotech firms and research institutions, investment in next-generation CAR T-cell platforms, and exploration of combination therapies are essential for leveraging these emerging opportunities.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the CAR T-cell therapy market globally?
• Which cancer types and indications are leading the adoption of CAR T-cell therapy?
• How are technological advancements shaping the competitive landscape of the CAR T-cell therapy market?
• Who are the key players in the CAR T-cell therapy market, and what strategies are they using to maintain their market positions?
• What are the emerging trends and future prospects in the global CAR T-cell therapy market?

Competitive Intelligence and Business Strategy:

Leading companies in the CAR T-cell therapy market, including Gilead Sciences, Novartis AG, and Bristol-Myers Squibb, are focusing on innovation, expanding clinical trials, and forming strategic collaborations to enhance their competitive position. These firms invest heavily in R&D to develop next-generation CAR T-cell therapies with better safety profiles and broader therapeutic applications. Partnerships with academic institutions, biopharma companies, and regulatory agencies are crucial for advancing clinical development and market access. Addressing manufacturing challenges, expanding treatment indications, and improving patient outcomes are key strategies for driving market growth and reinforcing the positions of major players in the evolving CAR T-cell therapy landscape.

Key Companies Profiled:

• Novartis AG
• Gilead Sciences Inc.
• Celgene Corporation
• bluebird bio, Inc.

CAR T-Cell Therapy Industry Research by Category

Product:

• Yescarta (axicabtagene ciloleucel)
• Kymriah (tisagenlecleucel)
• JCAR017 (lisocabtagene maraleucel)
• bb2121

Indication:

• Relapsed Large B-cell Lymphoma
• Acute Lymphoblastic Leukemia (ALL)
• Multiple Myeloma

End User:

• CAR T-Cell Therapy at Hospitals
• CAR T-Cell Therapy at Cancer Treatment Centers

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope
3. Key Success Factors
3.1. Iceberg Analysis
3.2. Revenue Opportunity Analysis
3.3. Parent Market Analysis
3.4. Pipeline Assessment
3.5. Potential Population Eligible for CAR T-cell Therapy, By Region
3.6. List of Authorized Treatment Centers in the U.S. & U.K.
3.7. Key Inclusion & Exclusion
4. Market Background
4.1. Macro-Economic Factors
4.1.1. Global GDP Outlook
4.1.2. Global Healthcare Expenditure Outlook
4.2. Forecast Factors - Relevance & Impact
4.2.1. Increasing Availability of CAR T-cell Therapy
4.2.2. Increasing Adoption of CAR T-cell Therapy
4.2.3. Superior Product Efficacy
4.2.4. Improving Reimbursement Scenario
4.2.5. Collaboration among Pharmaceutical and Biopharmaceutical Companies
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
5. COVID-19 Crisis Impact Analysis
5.1. Current COVID-19 Probable Future Impact
5.2. Current GDP Projection and Probable Impact
5.3. Current Economic Projection as compared to 2008 Economic analysis
5.4. COVID19 and Impact Analysis
5.4.1. Revenue By Product
5.4.2. Revenue By Indication
5.4.3. Revenue By End User
5.4.4. Revenue By Country
6. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,
6.1. Historical Market Value (US$Mn) Analysis, 2019-2023
6.2. Current and Future Market Value (US$Mn) Projections, 2024-2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By Product
7.1. Introduction/Key Findings
7.2. Historical Market Value (US$Mn) Analysis, By Product, 2019-2023
7.3. Current and Future Market Value (US$Mn) Projections, By Product, 2024-2033
7.3.1. Yescarta (axicabtagene ciloleucel)
7.3.2. Kymriah (tisagenlecleucel)
7.3.3. JCAR017 (lisocabtagene maraleucel)
7.3.4. bb2121
7.4. Market Attractiveness By Product
8. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By Indication
8.1. Introduction/Key Findings
8.2. Historical Market Value (US$Mn) Analysis, By Indication, 2019-2023
8.3. Current and Future Market Value (US$Mn) Projections, By Indication, 2024-2033
8.3.1. Relapsed Large B-cell Lymphoma
8.3.2. Acute Lymphoblastic Leukemia (ALL)
8.3.3. Multiple Myeloma
8.4. Market Attractiveness By Indication
9. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By End User
9.1. Introduction/Key Findings
9.2. Historical Market Value (US$Mn) Analysis, By End User, 2019-2023
9.3. Current and Future Market Value (US$Mn) Projections, By End User, 2024-2033
9.3.1. Hospitals
9.3.2. Cancer Treatment Centers
9.4. Market Attractiveness By End User
10. Global Car T cell Therapy Market Value (Size US$Mn) Analysis 2019-2023 and Forecast 2024-2033,By Region
10.1. Introduction/Key Findings
10.2. Historical Market Value (US$Mn) Analysis, By Region, 2019-2023
10.3. Current Market Size (US$Mn) Analysis and Forecast By Region, 2024-2033
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. Middle East & Africa
10.4. Market Attractiveness By Region
11. North America Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033
11.1. Introduction
11.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
11.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Product
11.3.3. By Indication
11.3.4. By End User
11.4 Market Attractiveness Analysis
12. Latin America Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033
12.1. Introduction
12.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
12.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Product
12.3.3. By Indication
12.3.4. By End User
12.4. Market Attractiveness Analysis
13. Europe Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
13.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
13.3.1. By Country
13.3.1.1. U.K.
13.3.1.2. Germany
13.3.1.3. France
13.3.1.4. Italy
13.3.1.5. Spain
13.3.1.6. Russia
13.3.1.7. BENELUX
13.3.1.8. Rest of Europe
13.3.2. By Product
13.3.3. By Indication
13.3.4. By End User
13.4. Market Attractiveness Analysis
14. South Asia Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
14.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Indonesia
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Product
14.3.3. By Indication
14.3.4. By End User
14.4. Market Attractiveness Analysis
15. East Asia Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
15.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Product
15.3.3. By Indication
15.3.4. By End User
15.4. Market Attractiveness Analysis
16. Oceania Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
16.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Product
16.3.3. By Indication
16.3.4. By End User
16.4. Market Attractiveness Analysis
17. Middle East & Africa Car T cell Therapy Market Analysis 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$Mn) Trend Analysis, By Market Taxonomy, 2019-2023
17.3. Current Market Size (US$Mn) Forecast By Market Taxonomy,2024-2033
17.3.1. By Country
17.3.1.1. Turkey
17.3.1.2. South Africa
17.3.1.3. GCC Countries
17.3.1.4. Rest of Middle East & Africa
17.3.2. By Product
17.3.3. By Indication
17.3.4. By End User
17.4. Market Attractiveness Analysis
18. Key and Emerging Countries Car T cell Therapy Market Analysis 2024-2033
18.1. U.S. Car T cell Therapy Market Analysis
18.1.1. By Product
18.1.2. By Indication
18.1.3. By End User
18.2. Canada Car T cell Therapy Market Analysis
18.2.1. By Product
18.2.2. By Indication
18.2.3. By End User
18.3. Brazil Car T cell Therapy Market Analysis
18.3.1. By Product
18.3.2. By Indication
18.3.3. By End User
18.4. Mexico Car T cell Therapy Market Analysis
18.4.1. By Product
18.4.2. By Indication
18.4.3. By End User
18.5. Argentina Car T cell Therapy Market Analysis
18.5.1. By Product
18.5.2. By Indication
18.5.3. By End User
18.6. U.K. Car T cell Therapy Market Analysis
18.6.1. By Product
18.6.2. By Indication
18.6.3. By End User
18.7. Germany Car T cell Therapy Market Analysis
18.7.1. By Product
18.7.2. By Indication
18.7.3. By End User
18.8. France Car T cell Therapy Market Analysis
18.8.1. By Product
18.8.2. By Indication
18.8.3. By End User
18.9. Italy Car T cell Therapy Market Analysis
18.9.1. By Product
18.9.2. By Indication
18.9.3. By End User
18.10. Spain Car T cell Therapy Market Analysis
18.10.1. By Product
18.10.2. By Indication
18.10.3. By End User
18.11. Russia Car T cell Therapy Market Analysis
18.11.1. By Product
18.11.2. By Indication
18.11.3. By End User
18.12. BENELUX Car T cell Therapy Market Analysis
18.12.1. By Product
18.12.2. By Indication
18.12.3. By End User
18.13. India Car T cell Therapy Market Analysis
18.13.1. By Product
18.13.2. By Indication
18.13.3. By End User
18.14. ASEAN Car T cell Therapy Market Analysis
18.14.1. By Product
18.14.2. By Indication
18.14.3. By End User
18.15. China Car T cell Therapy Market Analysis
18.15.1. By Product
18.15.2. By Indication
18.15.3. By End User
18.16. Japan Car T cell Therapy Market Analysis
18.16.1. By Product
18.16.2. By Indication
18.16.3. By End User
18.17. South Korea Car T cell Therapy Market Analysis
18.17.1. By Product
18.17.2. By Indication
18.17.3. By End User
18.18. Australia Car T cell Therapy Market Analysis
18.18.1. By Product
18.18.2. By Indication
18.18.3. By End User
18.19. New Zealand Car T cell Therapy Market Analysis
18.19.1. By Product
18.19.2. By Indication
18.19.3. By End User
18.20. GCC Countries Car T cell Therapy Market Analysis
18.20.1. By Product
18.20.2. By Indication
18.20.3. By End User
18.21. Turkey Car T cell Therapy Market Analysis
18.21.1. By Product
18.21.2. By Indication
18.21.3. By End User
18.22. South Africa Car T cell Therapy Market Analysis
18.22.1. By Product
18.22.2. By Indication
18.22.3. By End Users
19. Market Structure Analysis
19.1. Market Analysis By Tier of Companies
19.2. Market Share Analysis By Key Players
19.2.1. Regional footprint of Players
19.2.2. Service Footprint by players
19.2.3. Channel Foot Print by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Deep Dive
20.2.1. Novartis AG
20.2.1.1. Overview
20.2.1.2. Product Portfolio
20.2.1.3. Profitability by Market Segments (Product /End User/Region)
20.2.1.4. Sales Footprint
20.2.1.5. Strategy Overview
20.2.1.5.1. Marketing Strategy
20.2.1.5.2. Service Strategy
20.2.1.5.3. End User Strategy
20.2.2. Gilead Sciences Inc.
20.2.2.1. Overview
20.2.2.2. Product Portfolio
20.2.2.3. Profitability by Market Segments (Product /End User/Region)
20.2.2.4. Sales Footprint
20.2.2.5. Strategy Overview
20.2.2.5.1. Marketing Strategy
20.2.2.5.2. Service Strategy
20.2.2.5.3. End User Strategy
20.2.3. Celgene Corporation
20.2.3.1. Overview
20.2.3.2. Product Portfolio
20.2.3.3. Profitability by Market Segments (Product /End User/Region)
20.2.3.4. Sales Footprint
20.2.3.5. Strategy Overview
20.2.3.5.1. Marketing Strategy
20.2.3.5.2. Service Strategy
20.2.3.5.3. End User Strategy
20.2.4. bluebird bio, Inc.
20.2.4.1. Overview
20.2.4.2. Product Portfolio
20.2.4.3. Profitability by Market Segments (Product /End User/Region)
20.2.4.4. Sales Footprint
20.2.4.5. Strategy Overview
20.2.4.5.1. Marketing Strategy
20.2.4.5.2. Service Strategy
20.2.4.5.3. End User Strategy
21. Assumptions & Acronyms
22. Research Methodology